针对性或免疫疗法后的前期与推迟的细胞还原性切除术:对外科手术后并发症的基于人口的倾向性得分匹配分析
Francesco Ditonno1,2, Eugenio Bologna1,3, Leslie Claire Licari1,3
1Department of Urology, Rush University Medical Center, 1725 W. Harrison Street, Suite 970, Chicago, IL, 60612, USA.
World journal of urology
|July 27, 2024
概括
转移性细胞癌 (mRCC) 系统治疗后的细胞还原性切除术 (CN) 导致的并发症比前期的CN要多. 延迟的CN显示了更高的整体,医疗和手术30天并发症率.
科学领域:
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
- 腎臟病學 (nephrology) 是一種醫學專業.
- 在瘤学瘤学.
背景情况:
- 转移性细胞癌 (mRCC) 的治疗通常涉及全身疗法和细胞还原性切除术 (CN).
- 与全身治疗相关的NC的最佳时间仍然是一个关键的临床问题.
研究的目的:
- 为了比较30天的术后并发症的发生率,在mRCC的第一线全身分子疗法 (SMT) 后,前期的CN和延期的CN之间.
- 根据CN的时间分析医疗和手术并发症率的差异.
主要方法:
- 从2011-2021年对基于人口的数据库 (PearlDiver Mariner) 的回顾性分析.
- 确定接受一线SMT (铁氨酸激酶抑制剂或免疫检查点抑制剂) 的mRCC患者.
- 倾向性得分匹配 (PSM) 用于比较接受前期CN与推迟CN (SMT后) 的队列.
主要成果:
- 在PSM之后,每个队列中的162名患者 (前期与延期CN) 被比较.
- 延迟的CN与与前期的CN (21%,p <0.01) 相比,与30天整体术后并发症率 (33.9%) 的显著上升有关.
- 医学 (26.5% vs. 14.2%,p < 0.01) 和外科 (14.8% vs. 7.4%,p = 0.03) 的并发症率在延迟CN组显著更高.
结论:
- 在一线SMT后的mRCC患者中推迟的CN与整体,医疗和手术后30天的术后并发症的增加率有关.
- 这些发现表明,前期的CN可能与较低的并发症概况有关.
- 在解释结果时,应考虑研究内在的追溯数据库分析的研究局限性.
相关概念视频
Kidney Transplant I: Introduction
A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
Kidney Transplant II: Surgical Procedure
Preoperative ManagementThe primary goals of preoperative management in kidney transplantation are to optimize the patient’s metabolic state and prepare them for surgery through diet adjustments, necessary dialysis, and tailored medical treatment. This phase also involves comprehensive infection screening and patient education about the surgical procedure and postoperative care to improve outcomes and adherence.Medical ManagementA comprehensive evaluation is required for both the living donor...


